---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026227"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:15:01.056937+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics amends Royalty Pharma loan, extends draw deadlines to Mar 31, 2023

## Summary
- Amendment extends deadline for Tranche 2 and Tranche 3 Term Loans from Dec 31, 2022 to Mar 31, 2023.
- Repayment amount for those tranches increased from 190% to 200% of principal as consideration.
- Original Loan Agreement provided up to $300M for omecamtiv mecarbil, aficamten, and working capital.

## SEC filing metadata
- accession: 0000950170-22-026227
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017022026227/0000950170-22-026227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017022026227/cytk-20221208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026227
- JSON: https://secwatch.observer/filing/0000950170-22-026227.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026227.txt

## Key facts
- Material Agreements
  CYTOKINETICS INC amended Second Amendment to Development Funding Loan Agreement with Royalty Pharma Development Funding, LLC (effective 2022-12-08).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Royalty Pharma Development Funding, LLC
  - Effective: 2022-12-08
  source text: The Amendment extends the deadline dates, from December 31, 2022, to March 31, 2023, for which each of the respective conditions of the Tranche 2 Term Loans and Tranche 3 Term Loans must occur in order for Cytokinetics to be able to draw on these loans.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017022026227/0000950170-22-026227-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.